| Application no. and date | 16818985.0 (espacenet) (Federated) (European Patent Register), 20161205 | | Patent/reg. no. and date | DK/EP 3386541, 20200708 | | Publication date | 20181017 | | Priority no. and date | EP 15198233, 20151207 | | EP pub. no. and date |
EP 3386541 20181017 | | Effective date | | | Applicant/owner | Merck Patent GmbH, Frankfurter Strasse 250
64293 Darmstadt, DE,
Pfizer Inc., 66 Hudson Boulevard East
New York, NY 10001-2192, US | | Applicant ref. no. | P74261DK01 | | Inventor | WEIGANDT, Markus, Trollblumenweg 22
68259 Mannheim, DE,
Fratarcangeli, Silvia, C.so Risorgimento 3
03024 Ceprano FR, IT,
RINALDI, Gianluca, Via Gino Silvestrini 9
00015 Monterotondo, IT,
DEL RIO, Alessandra, Via lldebrando Vivanti 108
00144 Roma, IT,
VOSS, Senta, An der Finnensiedlung 1
55122 Mainz, DE | | Representative | Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, DK | | Opponent | | | IPC Class | A61K 39/395 (2006.01) , C07K 16/28 (2006.01) | | Title | VANDIG FARMACEUTISK FORMULERING OMFATTENDE ANTI-PD-1-ANTISTOF AVELUMAB | | Int. application no. | EP2016002040 | | Int. publication no. | WO2017097407 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
